Contemporary diagnosis and management of vestibular migraine: a systematic review of conventional and CGRP-targeted therapies.

Vestibular migraine (VM) causes recurring vertigo and significant disability for many patients. Traditional treatments vary in effectiveness, leaving some individuals without relief. New therapies targeting calcitonin gene-related peptide (CGRP) show promise for improving outcomes. This systematic review examined the current understanding of VM diagnosis and treatment options. Researchers analyzed various study types, including randomized trials and observational studies. They focused on how well conventional treatments compare to CGRP-targeted therapies. The findings suggest that while standard medications help some patients, CGRP treatments may offer better results for others. The review highlights the need for further research in this area. Ultimately, understanding and treating VM can greatly enhance patients' quality of life. Improved diagnosis and treatment options are crucial for managing this debilitating condition effectively. This research aims to guide clinicians in making informed decisions for their patients with vestibular migraine. Clinical relevance: This research indicates that CGRP-targeted therapies may improve management of vestibular migraine, offering new hope for patients struggling with traditional treatments.